作为自身免疫性肝炎的第一线治疗方法,mycophenolate mofetil与azathioprine:一个比较的系统审查和元分析
在PubMed上查看摘要
概括
此摘要是机器生成的。比阿扎西奥普林 (AZA) 提供更有效和更安全的第一线治疗自身免疫性肝炎 (AIH). 货币货币基金带来了更高的缓解率和更少的严重不良事件,改善了患者的结果.
科学领域
- 肝病学
- 免疫学
- 药理学
背景情况
- 自免疫性肝炎 (AIH) 是一种慢性肝病,其特征是免疫媒介的炎症和损伤.
- 标准治疗包括阿扎西奥普林 (AZA) 和类固醇,但对没有反应的人寻求替代方案.
研究的目的
- 为了比较mycophenolate mofetil (MMF) 与AZA作为AIH的第一线治疗的疗效和安全性.
- 评估治疗结果,包括缓解率和不良事件.
主要方法
- 对之前未接受治疗的AIH患者的MMF和AZA进行比较的研究进行了系统审查.
- 通过完全生化缓解 (CBR),不反应和复发率来评估疗效.
- 通过导致停止治疗的严重不良事件的发生率来评估安全性.
主要成果
- 分析了4项涉及512名患者的研究.
- 与AZA相比,MMF显著提高了短期 (OR 2.56) 和长期 (OR 5.51) 的CBR率.
- 治疗MMF的严重不良事件发生率显著降低 (OR 0. 15).
结论
- 基于MMF的AIH的第一线治疗比基于AZA的疗法更有前途.
- 货币货币基金表现出卓越的有效性,实现更高的CBR率.
- 提供更好的安全性,减少需要停止治疗的严重不良事件.
相关概念视频
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

